HeartBeam inc (BEAT)
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
$0.43+1.59%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - SpecialtiesSnapshot 2026-09-04
QuarterlyIQ Insights · BEAT
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
A larger daily loss that occurred about once in every 20 trading days.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Model as of 2026-09-04 · Compared with 8 industry peers · Company calendar date is not available
BEAT — officer change
Dated 2026-08-06
CFO — Mr. Eno: Mr. Eno departed the company and entered into a Separation Agreement.
Why it matters: Management plans to share more about the strategy to license the 3D ECG platform. This could clarify their path to global adoption.
Supportive ifManagement will talk about licensing deals or partnerships in the August call.
Worry ifNo new information or partnerships are announced during the call.
Why it matters: This call will explain how HeartBeam wants to grow its ECG platform worldwide.
Supportive ifManagement will share details about partnerships for the ECG platform in the Q2 call.
Worry ifNo clear strategy or partnerships are announced during the Q2 call.
Why it matters: The restructuring aims to improve efficiency and reduce costs. Its success will affect financial health.
Watch forOperating income is higher. This shows the restructuring is working.
Also watch forOperating income gets worse or stays the same. This means the restructuring is not working.
Why it matters: Details on the strategy will show how HeartBeam plans to grow its market reach. This is key for future revenue.
Supportive ifManagement provides a clear plan for licensing the 3D ECG platform to partners.
Worry ifThe next conference call will not give a clear strategy or timeline.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$286 on $10,000 · ±2.9% | How much price usually moves either way. |
| Bad day | $830 loss on $10,000 · 8.3% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,779 loss on $10,000 · 87.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: The company plans to share more about its strategy to expand its ECG platform. This could impact market adoption and growth.
Supportive ifA clear plan was shared in the August earnings call. It shows how to expand in the market.
Worry ifThe earnings call had unclear details. This caused uncertainty about the strategy.
Why it matters: The recent debt issuance could affect HeartBeam's cash flow and ability to invest in growth. Monitoring this will show if the capital allocation is effective.
Watch forHeartBeam reports better cash flow. This follows their debt issuance and investments.
Also watch forHeartBeam struggles with cash flow or fails to utilize the funds effectively.
Why it matters: The public offering aims to fund commercialization of the 12-lead ECG system. Revenue updates will indicate progress.
Supportive ifManagement reports higher revenue from selling the 12-lead ECG system.
Worry ifRevenue does not grow or falls even with funding from the public offering.
Why it matters: FDA clearance would validate HeartBeam's technology and open new market opportunities. This is vital for growth.
Supportive ifFDA grants clearance for the heart attack detection indication.
Worry ifFDA denies clearance or delays the review process for heart attack detection.
Why it matters: The success of the stock offering could provide funds for key projects, impacting future growth.
Supportive ifThe public offering is done. The money will be used for commercialization and development.
Worry ifThe offering was not completed. There was a big drop in expected money.
Why it matters: If HeartBeam sells more products, it could make more money.
Supportive ifManagement says there is good progress in selling the FDA-cleared 12-lead ECG system.
Worry ifNo progress is reported. This shows ongoing problems in selling the products.
Why it matters: Fixing the delisting notice is important for HeartBeam's stock and for investor trust.
Worry ifHeartBeam provides a plan to regain compliance with Nasdaq listing standards.
Less concerning ifFailure to address the delisting notice or further decline in stock price.
Why it matters: Improving cash flow is crucial for HeartBeam to manage losses. It shows financial health.
Supportive ifCash from operations improves to less than negative $3.0M in Q2 earnings.
Worry ifCash from operations worsens or stays worse than negative $3.6M in Q2 earnings.
Why it matters: A smooth transition is key for stability after the CEO's departure. It affects investor confidence.
Watch forAnnouncement of a new CEO or interim leader with a clear plan for the future.
Also watch forThere is still uncertainty about when a new CEO will be chosen.
Why it matters: This call will provide insights into HeartBeam's financial health and future plans. Investors will look for signs of growth or continued losses.
Watch forEarnings report shows revenue growth or a path to profitability.
Also watch forThe earnings report shows ongoing losses. There is no clear plan to improve.
Why it matters: The company got a notice to be delisted. How it responds will affect investor trust.
Worry ifThe delisting notice was resolved successfully. The stock price is stable above the needed level.
Less concerning ifThe company still does not meet Nasdaq rules. This could lead to being delisted.
Why it matters: Advancing heart attack detection could open new markets and revenue streams. This is a key focus for management.
Supportive ifManagement gives updates on FDA progress and clinical study results. These help detect heart attacks.
Worry ifThere are no updates on FDA progress. Clinical studies show negative results.